CELL INTELLIGENCE · 肿瘤细胞治疗研究

T lymphocytes represent an emerging class of cellular immunotherapy with preclinical promise to treat cancer, notably neuroblastoma. The innate-like immune cell subset demonstrates inherent cytoxicity toward tumor cells independent of MHC recognition, enabling allogeneic administration of healthy donor-derived T cell therapies. A current limitation is the substantial interindividual T cell expansion variation among leukocyte collections. Overcoming this limitation will enable realization of the full potential of allogeneic T-based cellular therapy. Here, we characterize T cell expansions from healthy adult donors and observe that highly potent natural killer (NK) lymphocytes expand with T cells under zoledronate and IL-2 stimulation. The presence of NK cells correlates with both the expansion potential of T cells and the overall potency of the T cell therapy. However, the potency of the cell therapy in combination with an antibody-based immunotherapeutic, dinutuximab, appears to be independent of T/NK cell content both in vitro and in vivo , which minimizes the implication of interindividual expansion differences toward efficacy. Collectively, these studies highlight the utility of maintaining the NK cell population within expanded T cell therapies and suggest a synergistic action of combined innate cell immunotherapy toward neuroblastoma.